avapro has been researched along with Disease Exacerbation in 28 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke." | 9.16 | A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. ( Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB, 2012) |
| " ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin." | 7.80 | Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "Osteoprotegerin (OPG) has recently been identified in atherosclerosis." | 5.33 | Association of osteoprotegerin with human abdominal aortic aneurysm progression. ( Golledge, J; Karan, M; Ketheesan, N; McCann, M; Moran, CS; Norman, P, 2005) |
| "To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke." | 5.16 | A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. ( Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB, 2012) |
| "We used a New Zealand white rabbit model of cationized bovine serum albumin (cBSA)-induced glomerulonephritis and then administered them metoprolol, irbesartan or acupuncture to evaluate the effectiveness of acupuncture treatment and preliminarily explore its potential mechanism." | 3.80 | "Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity. ( An, P; Dang, HM; Shi, XM; Wu, XL; Ye, BY, 2014) |
| " ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin." | 3.80 | Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| "The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "133 patients with type 2 diabetic nephropathy (age, 66 ± 8 years; 76% men) from 17 centers in Spain." | 2.78 | Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. ( Barrio, V; Cachofeiro, V; de Vinuesa, SG; Fernandez Juarez, G; Fernández Vega, F; Goicoechea, M; Gutierrez, E; Luño, J; Nieto, J; Praga, M; Tato, A, 2013) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| " At the end of the follow-up, blood samples were taken for plasma lipid dosing and aorta samples for histology." | 1.38 | Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. ( Breisse, M; Canet-Soulas, E; Corot, C; Kaye, E; Lancelot, E; Majd, Z; Provost, N; Sigovan, M, 2012) |
| "Osteoprotegerin (OPG) has recently been identified in atherosclerosis." | 1.33 | Association of osteoprotegerin with human abdominal aortic aneurysm progression. ( Golledge, J; Karan, M; Ketheesan, N; McCann, M; Moran, CS; Norman, P, 2005) |
| "Two patients with pheochromocytoma are described in whom treatment with a high dose of an angiotensin receptor blocker was associated with cessation of tumor growth as assessed by serial CT scanning and plasma norepinephrine estimation." | 1.33 | AT2 receptor stimulation may halt progression of pheochromocytoma. ( Appleton, DS; Ashby, MJ; Balan, KK; Brown, MJ; Mackenzie, IS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (60.71) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, P | 1 |
| Dang, HM | 1 |
| Shi, XM | 1 |
| Ye, BY | 1 |
| Wu, XL | 1 |
| Kjaergaard, KD | 1 |
| Peters, CD | 1 |
| Jespersen, B | 1 |
| Tietze, IN | 1 |
| Madsen, JK | 1 |
| Pedersen, BB | 1 |
| Novosel, MK | 1 |
| Laursen, KS | 1 |
| Bibby, BM | 1 |
| Strandhave, C | 1 |
| Jensen, JD | 1 |
| Damman, K | 1 |
| Perez, AC | 1 |
| Anand, IS | 1 |
| Komajda, M | 1 |
| McKelvie, RS | 1 |
| Zile, MR | 1 |
| Massie, B | 1 |
| Carson, PE | 1 |
| McMurray, JJ | 1 |
| Takahashi, A | 1 |
| Fukusumi, Y | 1 |
| Yamazaki, M | 1 |
| Kayaba, M | 1 |
| Kitazawa, Y | 1 |
| Tomita, M | 1 |
| Kawachi, H | 1 |
| Zhao, Y | 1 |
| Fukao, K | 1 |
| Zhao, S | 1 |
| Watanabe, A | 1 |
| Hamada, T | 1 |
| Yamasaki, K | 1 |
| Shimizu, Y | 1 |
| Kubo, N | 1 |
| Ukon, N | 1 |
| Nakano, T | 1 |
| Tamaki, N | 1 |
| Kuge, Y | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 3 |
| Gansevoort, RT | 1 |
| Vieitez, P | 1 |
| Gómez, O | 1 |
| Uceda, ER | 1 |
| Vera, ME | 1 |
| Molina-Holgado, E | 1 |
| Persson, F | 1 |
| Rossing, P | 1 |
| Hovind, P | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Tarnow, L | 1 |
| Parving, HH | 5 |
| Chen, HB | 1 |
| Lu, JX | 1 |
| Li, Q | 1 |
| Bao, YQ | 1 |
| Tang, JL | 1 |
| Lu, HJ | 1 |
| Xiang, KS | 1 |
| Jia, WP | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Heras, M | 1 |
| Saiz, A | 1 |
| Pardo, J | 1 |
| Fernández-Reyes, MJ | 1 |
| Sánchez, R | 1 |
| Alvarez-Ude, F | 1 |
| Beer, C | 1 |
| Blacker, D | 1 |
| Bynevelt, M | 1 |
| Hankey, GJ | 1 |
| Puddey, IB | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 1 |
| Sigovan, M | 1 |
| Kaye, E | 1 |
| Lancelot, E | 1 |
| Corot, C | 1 |
| Provost, N | 1 |
| Majd, Z | 1 |
| Breisse, M | 1 |
| Canet-Soulas, E | 1 |
| Fernandez Juarez, G | 1 |
| Luño, J | 1 |
| Barrio, V | 1 |
| de Vinuesa, SG | 1 |
| Praga, M | 1 |
| Goicoechea, M | 1 |
| Cachofeiro, V | 1 |
| Nieto, J | 1 |
| Fernández Vega, F | 1 |
| Tato, A | 1 |
| Gutierrez, E | 1 |
| Suzuki, H | 1 |
| Palmer, AJ | 4 |
| Annemans, L | 3 |
| Roze, S | 3 |
| Lamotte, M | 2 |
| Rodby, RA | 3 |
| Ritz, E | 1 |
| Lapuerta, P | 2 |
| Chen, R | 2 |
| Gabriel, S | 2 |
| Carita, P | 2 |
| Llewelyn, DE | 1 |
| Garcia-Puig, J | 1 |
| Moran, CS | 1 |
| McCann, M | 1 |
| Karan, M | 1 |
| Norman, P | 1 |
| Ketheesan, N | 1 |
| Golledge, J | 1 |
| Burnier, M | 2 |
| Zanchi, A | 1 |
| Janiak, P | 1 |
| Bidouard, JP | 1 |
| Cadrouvele, C | 1 |
| Poirier, B | 1 |
| Gouraud, L | 1 |
| Grataloup, Y | 1 |
| Pierre, F | 1 |
| Bruneval, P | 1 |
| O'Connor, SE | 1 |
| Herbert, JM | 1 |
| Frei, A | 1 |
| Hess, B | 1 |
| Valentine, WJ | 1 |
| Tucker, DM | 1 |
| Ray, JA | 1 |
| Laville, M | 1 |
| Brown, MJ | 1 |
| Mackenzie, IS | 1 |
| Ashby, MJ | 1 |
| Balan, KK | 1 |
| Appleton, DS | 1 |
| Coronel, F | 1 |
| Cigarrán, S | 1 |
| García-Mena, M | 1 |
| Herrero, JA | 1 |
| Calvo, N | 1 |
| Pérez-Flores, I | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
| Lehnert, H | 1 |
| Bröchner-Mortensen, J | 1 |
| Gomis, R | 1 |
| Andersen, S | 1 |
| Arner, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)[NCT00317915] | Phase 3 | 0 participants | Interventional | Completed | |||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for avapro and Disease Exacerbation
| Article | Year |
|---|---|
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Com | 2002 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
8 trials available for avapro and Disease Exacerbation
| Article | Year |
|---|---|
Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Biphenyl Compounds; Disease Progression | 2014 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
Topics: Adult; Aged; Albuminuria; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2008 |
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; | 2012 |
Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 2013 |
How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetic Angiopathies; Diabet | 2004 |
[Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Disease | 2008 |
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compou | 2001 |
18 other studies available for avapro and Disease Exacerbation
| Article | Year |
|---|---|
"Qufeng Tongluo" acupuncture prevents the progression of glomerulonephritis by decreasing renal sympathetic nerve activity.
Topics: Acupuncture Therapy; Animals; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Glome | 2014 |
Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Disease Progression; Female; Glom | 2014 |
Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Diseas | 2014 |
Irbesartan attenuates atherosclerosis in Watanabe heritable hyperlipidemic rabbits: noninvasive imaging of inflammation by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Autoradiography; Biphenyl Compounds; Body Weight; | 2015 |
Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, West | 2008 |
The protective effect of the RAS inhibitor on diabetic patients with nephropathy in the context of VEGF suppression.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cross-Sectional Studies; Diabetes | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
[Rapidly progressive renal failure as the onset of an IgA nephropathy in an elderly patient].
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Biphenyl Compounds; Disease Progression; Diuretics; Doxaz | 2011 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Biphenyl Comp | 2012 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patien
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Chann | 2004 |
Association of osteoprotegerin with human abdominal aortic aneurysm progression.
Topics: Adult; Aged; Angiotensin II; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apoptosis; Biopsy; Biphen | 2005 |
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; | 2006 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cost-Benefit Analysis; Dia | 2006 |
AT2 receptor stimulation may halt progression of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Disease | 2006 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |